m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is lethal and possesses limited therapeutic options. Platinum-based chemotherapy—with or without immune checkpoint inhibitors (anti-PDs)—is the current first-line therapy for SCLCs; however, its associated outcomes are heterogeneous. N(6)-methyladenosine (m(...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhihui, Zhang, Chaoqi, Luo, Yuejun, Wu, Peng, Zhang, Guochao, Zeng, Qingpeng, Wang, Lide, Yang, Zhaoyang, Xue, Liyan, Zheng, Bo, Zeng, Hua, Tan, Fengwei, Xue, Qi, Gao, Shugeng, Sun, Nan, He, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607595/
https://www.ncbi.nlm.nih.gov/pubmed/34802443
http://dx.doi.org/10.1186/s12916-021-02148-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607595/
https://www.ncbi.nlm.nih.gov/pubmed/34802443
http://dx.doi.org/10.1186/s12916-021-02148-5

Ejemplares similares